Drug Profile
Eculizumab biosimilar - ISU Abxis
Alternative Names: ISU-305Latest Information Update: 21 Jun 2023
Price :
$50
*
At a glance
- Originator ISU Abxis
- Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antihypertensives; Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Atypical Haemolytic Uraemic Syndrome; Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 16 Jun 2023 Phase I development is ongoing for Atypical haemolytic uraemic syndrome in Australia and New Zealand (ISU Axis pipeline, June 2023)
- 16 Jun 2023 Phase I developments is ongoing for Paroxysmal nocturnal haemoglobinuria in Australia and New Zealand (ISU Axis pipeline, June 2023)
- 16 Jun 2023 Preclinical development is ongoing for Paroxysmal nocturnal haemoglobinuria in Sounth Korea (ISU Axis pipeline, June 2023)